Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 3/20 | 0.41 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.36 |
| ▸ | GCK | P35557 | 3/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | EDNRA | P25101 | 4/20 | 0.33 |
| ▸ | EDNRB | P24530 | 3/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ELOVL6 | Q9H5J4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13358934 | 0.78 | CA2 (0.32) | CHRNA7GCK | |
| SCHEMBL12186152 | 0.77 | GPR119 (0.40) | GCKKDM4EALDH1A1GAAMAPT | |
| SCHEMBL10105631 | 0.77 | CHRNA7 (0.45) | CHRNA7EDNRAEDNRBKDM4EALDH1A1 | |
| SCHEMBL5002545 | 0.75 | FABP3 (0.40) | CHRNA7EDNRAEDNRBKDM4EALDH1A1 | |
| SCHEMBL6179639 | 0.75 | CA12 (0.55) | CHRNA7EDNRAKDM4EALDH1A1LMNA | |
| SCHEMBL1040641 | 0.75 | CHRNA7 (0.38) | CHRNA7EDNRAEDNRBKDM4EALDH1A1 | |
| Potassium SCHEMBL5039366 | 0.74 | CA12 (0.53) | CHRNA7EDNRAKDM4EALDH1A1LMNA | |
| SCHEMBL12186143 | 0.74 | CHRNA7 (0.38) | CHRNA7GCKEDNRAEDNRBKDM4E | |
| SCHEMBL5039363 | 0.74 | CA12 (0.53) | CHRNA7EDNRAKDM4EALDH1A1LMNA | |
| SCHEMBL423199 | 0.74 | GPR119 (0.39) | KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754226-B2 | Piperidinyl-substituted lactams as GPR119 modulators | ARRAY BIOPHARMA INC. (US) | 2014-06-17 | — | — | US | disclosed |
| US-20130158009-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | ARRAY BIOPHARMA, INC. | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158009-A1 | PIPERIDINYL-SUBSTITUTED LACTAMS AS GPR119 MODULATORS | GPR119, GPR139, GPR39 | CHRNA7 1230/4885MCOLN3 2401/4885GCK 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.